Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cy5-bis-P0101-125
- Development stage
- Preclinical
- Lead developer
- Leiden University Medical Center
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
Cy5-bis-P0101-125 is a dimeric fluorescent peptide tracer developed by the Leiden University Medical Center (LUMC) for intraoperative nerve visualization during nerve-sparing surgery. It specifically targets myelin protein zero (P0), the most abundant protein in peripheral myelin. By dimerizing the homotypic P0 protein-based peptide sequence P0101-125 using a bifunctional Cy5 fluorescent dye, Cy5-bis-P0101-125 achieves enhanced binding affinity and fluorescence intensity compared to its monomeric counterpart, facilitating real-time fluorescence-guided surgical interventions to prevent accidental nerve damage.
- Other names
- dimeric Cy5-(P0101-125)2dimeric Cy5-bis-P0101-125
Beyond the preview
Go deeper on Cy5-bis-P0101-125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cy5-bis-P0101-125.